Literature DB >> 34411294

A 2-year prospective analysis of insomnia as a mediator of the relationship between androgen deprivation therapy and perceived cognitive function in men with prostate cancer.

Sheila N Garland1,2, Josée Savard3,4, Sarah L Eisel5, Richard J Wassersug6, Nicholas J Rockwood7, John Thoms2, Heather S L Jim5, Brian D Gonzalez5.   

Abstract

BACKGROUND: Androgen deprivation therapy (ADT) may affect cognitive function in men with prostate cancer (PCa). This study examined whether insomnia symptoms mediate the relationship between ADT and perceived cognitive function and whether depressive symptoms, fatigue severity, and physical activity moderate the strength of this relationship.
METHODS: This was a prospective study of ADT recipients (n = 83) who were matched with control patients with PCa who were not on ADT (n = 92) and with controls with no history of cancer (n = 112) over a 2-year follow-up period. Perceived cognitive function and satisfaction were assessed with the Everyday Cognition Scale. Insomnia was assessed with the Insomnia Severity Index. Multilevel mediation analyses were conducted to estimate the indirect effect of ADT on perceived cognitive function through insomnia symptoms. Exploratory moderated mediation analyses assessed whether the indirect effect of ADT on perceived cognitive function through insomnia symptoms was dependent on levels of fatigue, depression, or physical activity.
RESULTS: Insomnia symptoms significantly mediated the relationship between receipt of ADT and perceived cognitive function (P < .001) and satisfaction with cognition (P < .001) after controlling for comorbidities. Men with greater fatigue had a more pronounced association of ADT with insomnia severity. Men with greater depressive symptoms had a stronger association between insomnia severity and worse perceived cognitive function. Physical activity was not a significant moderator of the relationship between ADT and perceived cognitive function.
CONCLUSIONS: Insomnia influenced the relationship between ADT and perceived cognitive abilities. Interventions to address insomnia, fatigue, and depression may improve perceived cognitive function.
© 2021 American Cancer Society.

Entities:  

Keywords:  androgen deprivation therapy; cognitive function; depression; fatigue; insomnia symptoms; physical activity; prostate cancer

Mesh:

Substances:

Year:  2021        PMID: 34411294      PMCID: PMC8664983          DOI: 10.1002/cncr.33850

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  33 in total

1.  Insomnia nature, diagnosis, and treatment.

Authors:  Charles M Morin; Ruth M Benca
Journal:  Handb Clin Neurol       Date:  2011

2.  The measurement of everyday cognition (ECog): scale development and psychometric properties.

Authors:  Sarah Tomaszewski Farias; Dan Mungas; Bruce R Reed; Deborah Cahn-Weiner; William Jagust; Kathleen Baynes; Charles Decarli
Journal:  Neuropsychology       Date:  2008-07       Impact factor: 3.295

3.  Cognitive Effects of Androgen Deprivation Therapy in Men With Advanced Prostate Cancer.

Authors:  Bulent Gunlusoy; Yasin Ceylan; Aslı Koskderelioglu; Muhtesem Gedizlioglu; Tansu Degirmenci; Pınar Ortan; Zafer Kozacioglu
Journal:  Urology       Date:  2017-02-07       Impact factor: 2.649

4.  Depressive symptomatology in men receiving androgen deprivation therapy for prostate cancer: a controlled comparison.

Authors:  Morgan Lee; Heather S Jim; Mayer Fishman; Babu Zachariah; Randy Heysek; Matthew Biagioli; Paul B Jacobsen
Journal:  Psychooncology       Date:  2014-06-13       Impact factor: 3.894

Review 5.  Physical Activity Throughout the Adult Life Span and Domain-Specific Cognitive Function in Old Age: A Systematic Review of Cross-Sectional and Longitudinal Data.

Authors:  Tobias Engeroff; Tobias Ingmann; Winfried Banzer
Journal:  Sports Med       Date:  2018-06       Impact factor: 11.136

6.  Prostate cancer treatments and their side effects are associated with increased insomnia.

Authors:  Josée Savard; Séverine Hervouet; Hans Ivers
Journal:  Psychooncology       Date:  2012-08-08       Impact factor: 3.894

7.  A Pan-Canadian practice guideline: prevention, screening, assessment, and treatment of sleep disturbances in adults with cancer.

Authors:  Doris Howell; Thomas K Oliver; Sue Keller-Olaman; Judith Davidson; Sheila Garland; Charles Samuels; Josée Savard; Cheryl Harris; Michèle Aubin; Karin Olson; Jonathan Sussman; James Macfarlane; Claudette Taylor
Journal:  Support Care Cancer       Date:  2013-05-25       Impact factor: 3.603

8.  Measurement of fatigue in cancer patients: development and validation of the Fatigue Symptom Inventory.

Authors:  D M Hann; P B Jacobsen; L M Azzarello; S C Martin; S L Curran; K K Fields; H Greenberg; G Lyman
Journal:  Qual Life Res       Date:  1998-05       Impact factor: 4.147

9.  Impact of Androgen Deprivation Therapy on Self-Reported Cognitive Function in Men with Prostate Cancer.

Authors:  Shireen Marzouk; Gary Naglie; George Tomlinson; Sarah Duff Canning; Henriette Breunis; Narhari Timilshina; Shabbir M H Alibhai
Journal:  J Urol       Date:  2018-03-01       Impact factor: 7.450

10.  Changes in physical functioning and muscle strength in men receiving androgen deprivation therapy for prostate cancer: a controlled comparison.

Authors:  Brian D Gonzalez; Heather S L Jim; Brent J Small; Steven K Sutton; Mayer N Fishman; Babu Zachariah; Randy V Heysek; Paul B Jacobsen
Journal:  Support Care Cancer       Date:  2015-11-13       Impact factor: 3.359

View more
  2 in total

1.  The relationship between sleep hygiene, mood, and insomnia symptoms in men with prostate cancer.

Authors:  Kathleen T Galvin; Sheila N Garland; Erik Wibowo
Journal:  Support Care Cancer       Date:  2022-01-22       Impact factor: 3.359

2.  Prospective Rates, Longitudinal Associations, and Factors Associated With Comorbid Insomnia Symptoms and Perceived Cognitive Impairment.

Authors:  Sheila N Garland; Hans Ivers; Josée Savard
Journal:  Front Neurosci       Date:  2022-01-24       Impact factor: 4.677

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.